Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care. London – 05 May 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive results from the innovative Salford Lung Study (SLS) in asthma, carried out […]
Follows regulatory submissions in US, EU and Canada London UK – 18 April 2017 – GSK [LSE/NYSE: GSK] today announced that Japan Vaccine Co., Ltd., a joint venture of GlaxoSmithKline and Daiichi Sankyo Co., Ltd., submitted a New Drug Application in Japan seeking approval for the candidate shingles vaccine, Shingrix, for the prevention of herpes […]
London UK and Lome, Togo – 18 April 2017 – GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) congratulate President Faure Gnassingbé, the Government and the people of Togo for becoming the first country in Africa recognized by the World Health Organization to have eliminated lymphatic filariasis (LF) as a public […]
The Sir Andrew Witty GSK Scholarships will be funded by GSK and run by the London School of Hygiene & Tropical Medicine 10-year agreement to fund 30 scholars from sub-Saharan Africa on a Master of Science programme London UK – 29 March 2017 – GSK has today announced a new partnership with the London School […]
Groundbreaking UK/US initiative will deliver first data within a year London UK – 23 March 2017 – UK Biobank today announced a major research initiative with GSK and the Regeneron Genetics Center (RGC) to generate genetic sequence data from the 500,000 volunteer participants in the UK Biobank resource. The initiative will enable researchers to gain […]
London UK – 01 March 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas. GSK has divested its anaesthesia portfolio to Aspen (excluding the US and Canada which had been previously divested) for £180m plus […]
London – 19 January 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company. He has agreed with GSK that he will leave the company later this year. Abbas joined GSK in 2008 and has held roles of increasing responsibility within the company’s pharmaceutical business. […]
London – 19 January 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Luke Miels has been appointed President, Global Pharmaceuticals, GSK. He will be responsible for a portfolio of medicines and vaccines with annual sales of more than £15 billion and operations in over 100 markets. Luke will report to Emma Walmsley, who is […]
AFRICA – 03 January 2017 – GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN) and certain of its subsidiaries (“Aspen”), which were the subject of announcements by both companies on 12 September 2016. GSK and Aspen have terminated their collaboration in Sub-Saharan Africa and […]
21 December 2015, London – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the completion of its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis Pharma AG (“Novartis Pharma”), a subsidiary of Novartis AG, following regulatory approval. The consideration payable by Novartis Pharma to GSK may reach up to $1,034 million and comprises a series […]